Nanomedicine and regenerative medicine approaches in osteoarthritis therapy

Aging Clin Exp Res. 2022 Oct;34(10):2305-2315. doi: 10.1007/s40520-022-02199-5. Epub 2022 Jul 22.

Abstract

Osteoarthritis (OA), the most common chronic joint disease, is a degenerative disease that affects 7% of the worldwide population, more than 500 million people all over the world. OA is the main factor of disability in elderly people which decreases the quality of life of patients. It is characterized by joint pain, low bone density, and deterioration of the joint structure. Despite ongoing novel advances in drug discovery and drug delivery, OA therapy is still a big challenge since there is no available effective treatment and the existing therapies mainly focus on pain and symptomatic management rather than improving and/or suppressing its progression. This review aims to summarize the currently available and novel emerging therapies for OA including regenerative medicine and nanotechnology-based materials and formulations at the clinical and experimental levels. Applications of regenerative medicine and novel technologies such as nanotechnology in OA treatments have opened a new window to support OA patients by offering treatments that could halt or delay OA progression satisfactorily or provide an effective cure in near future. Nanomedicine and regenerative medicine suggest novel alternatives in the regeneration of cartilage, repair of bone damage, and control of chronic pain in OA therapy.

Keywords: Arthrocen; Liposome; Nanomedicine; Osteoarthritis; Regenerative medicine; Review.

Publication types

  • Review

MeSH terms

  • Aged
  • Humans
  • Nanomedicine
  • Osteoarthritis* / therapy
  • Quality of Life
  • Regenerative Medicine*